Blog .

Devicare raises USD$3M in a Series A funding led by Advanced MedTech. Ship2B, Emesa and Juan Knuth participate in the round

Inveniam has advised in the round and the closing of the investment of Ship2B.

Life Sciences

We are happy to announce that our colleagues from Devicare have closed a USD$3M Series A funding that will advance the development of Lit-Control, a non-surgical solution to kidney stones. The operation has been led by the Asian giant Advanced MedTech, owned by Temasek Holdings, Singapore’s sovereign wealth fund.

The round has also counted with the participation of Ship2B, through its impact fund Equity4Good, which in turn is co-financed by the European Investment Fund (EIF). In addition, investors already present in the capital, such as Emesa -Emilio Cuatrecasas’ investment company- or Juan Knuth -former owner of Palex Medical- have again supported the financing of the company.

We at Inveniam Group are very delighted to have been able to contribute to this great achievement. We wish you all the best in your future endeavours.

Read this article for more information.